Alnylam Pharmaceuticals (ALNY) 118.00 $ALNY
Alnylam Reports Positive Patisiran Results, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:02PM CDT
Alnylam Pharmaceuticals (ALNY) announced encouraging results from its phase II study on patisiran.
BIIB: 423.57 (+1.46), ALNY: 118.00 (-2.70), AMGN: 169.10 (+0.64), SNY: 51.59 (+0.03)
Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 22, 12:21PM CDT
Amgen's (AMGN) first quarter 2015 results were impressive and the company raised its earnings outlook for the year.
BIIB: 423.57 (+1.46), ALNY: 118.00 (-2.70), GILD: 104.18 (-1.02), MDCO: 27.84 (+0.25), AMGN: 169.10 (+0.64), AMPE: 2.89 (+0.20), ABBV: 64.52 (+0.91), ATHX: 1.34 (+0.01)
Can the Rally in Alnylam Pharmaceuticals (ALNY) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 6:29AM CDT
Can the Rally in Alnylam Pharmaceuticals (ALNY) Shares Continue?
ALNY: 118.00 (-2.70)
Alnylam Pharmaceuticals
at Investor's Business Daily - Tue Apr 21, 5:48PM CDT
Alnylam Pharmaceuticals (ALNY) disclosed positive midstage testing results for its neurological drug patisiran, used to treat the potentially fatal genetic disorder, transthyretin-mediated amyloidosis. Shares rose rose 1.7% to 120.70.
ALNY: 118.00 (-2.70)
Alnylam Pharmaceuticals Rises 1.70% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Apr 21, 5:16PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $119.01 to a high of $132.99. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $123.72 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 118.00 (-2.70)
Why Alnylam Pharmaceuticals, Inc. Shares Are Soaring Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 21, 12:36PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What's happening: Shares in Alnylam...
ALNY: 118.00 (-2.70), SNY: 51.59 (+0.03)
Alnylam Says Neurological Drug Passes Midstage Study
at Investor's Business Daily - Tue Apr 21, 12:22PM CDT
Alnylam Pharmaceuticals (ALNY) disclosed positive midstage testing results for its neurological drug patisiran, used to treat the potentially fatal disease transthyretin-mediated amyloidosis (TTM), a genetic disorder. The company said patisiran...
ALNY: 118.00 (-2.70)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:22AM CDT
HOG: 56.23 (+0.51), TNXP: 6.73 (+0.21), ALNY: 118.00 (-2.70), LRE: 8.43 (+0.08), LRCX: 78.36 (+0.52), MYL: 72.40 (-1.67), NVGN: 7.40 (-0.30), BIOC: 3.15 (+0.02), NBG: 1.19 (+0.12), VLTC: 15.14 (-1.04), FTNT: 38.07 (-0.01), BCLI: 4.29 (-0.09), SANM: 21.09 (+0.40)
Alnylam's patisiran shows promise of halting neuropathy progression in patients with genetic disorder
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 7:47AM CDT
ALNY: 118.00 (-2.70)
Alnylam Reports 12-Month Clinical Data from Phase 2 Open Label Extension (OLE) Study of Patisiran, an Investigational RNAi Therapeutic for Patients with Familial Amyloidotic Polyneuropathy (FAP)
Business Wire - Tue Apr 21, 5:00AM CDT
--- Based on Promising Results, Company Now Plans to Report 18-Month OLE Clinical Data in Late 2015 -
ALNY: 118.00 (-2.70)
Big Pharmas' Dirty Little Secret About Cholesterol Lowering Drugs
Mark Chapman - at Seeking Alpha - Wed Apr 15, 10:19AM CDT
ESPR: 100.53 (-2.60), ALNY: 118.00 (-2.70), MDCO: 27.84 (+0.25), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)
Alnylam Reports Publication of New Data on Hemophilia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 3:45PM CDT
Alnylam (ALNY) announced that pre-clinical results on ALN-AT3 were published in Nature Medicine.
BIIB: 423.57 (+1.46), ALNY: 118.00 (-2.70), AMGN: 169.10 (+0.64), AFFX: 12.57 (-0.13)
Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3, an Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)
Business Wire - Mon Apr 13, 10:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication in Nature Medicine of pre-clinical results with ALN-AT3, an investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD). The paper, titled "An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia" (Sehgal et al., Nat Med, doi:10.1038/nm.3847), documents a broad set of pre-clinical data supporting the clinical advancement of ALN-AT3. Among the many findings reported, subcutaneous administration of ALN-AT3 led to potent, dose-dependent, and durable knockdown of AT in wild-type mice, hemophilia A mice, and non-human primates (NHPs). In addition, ALN-AT3 treatment improved hemostasis in hemophilia mice and normalized thrombin generation in a non-human primate "inhibitor" model of hemophilia A (HA). Furthermore, long-term ALN-AT3 administration - even at highly exaggerated doses - was shown to be well tolerated in hemophilia mice, supporting a wide therapeutic index in the disease setting.
ALNY: 118.00 (-2.70)
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 5.96% Rise
Comtex SmarTrend(R) - Fri Apr 10, 4:51PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $108.00 to a high of $114.69. Yesterday, the shares gained 6.0%, which took the trading range above the 3-day high of $109.08 on volume of 726,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 118.00 (-2.70)
Upcoming Events: RNAi And Remyelination At AAN And Pivotal Data From Eleven
EP Vantage - at Seeking Alpha - Thu Apr 09, 4:03PM CDT
Welcome to your weekly digest of approaching regulatory and clinical readouts. Several companies will present data on closely-watched products at the annual meeting of the American Academy of Neurology, taking place in the US capital the week after...
BIIB: 423.57 (+1.46), ALNY: 118.00 (-2.70), GWPH: 113.04 (-0.05)
Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 7:46AM CDT
Alnylam Pharmaceuticals (ALNY) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 49 out of more than 250 industries.
ALNY: 118.00 (-2.70)
Alnylam to Webcast Presentation at 14th Annual Needham Healthcare Conference
Business Wire - Wed Apr 08, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 12:10 p.m. ET at the Westin Grand Central Hotel in New York City.
ALNY: 118.00 (-2.70)
Infinity Pharmaceuticals Exercises Duvelisib Royalty Option - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 01, 2:20PM CDT
Infinity Pharmaceuticals, Inc. announced that it has exercised its option to buy out all future royalty obligations related to the sales of its candidate, duvelisib.
ALNY: 118.00 (-2.70), INFI: 14.71 (-0.28), ABBV: 64.52 (+0.91)
Hospira Presents Data on Retacrit, an Epogen Biosimilar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 9:30AM CDT
Hospira, Inc. presented data from two studies on a proposed biosimilar, Retacrit.
JNJ: 100.43 (+0.13), ALNY: 118.00 (-2.70), PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), HSP: 87.80 (+0.04)
After Yesterday's Decline of 5.13%, Alnylam Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Mon Mar 23, 5:24PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $110.52 to a high of $116.49. Yesterday, the shares fell 5.1%, which took the trading range below the 3-day low of $111.34 on volume of 829,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALNY: 118.00 (-2.70)
Alnylam Reports Positive Patisiran Results, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:02PM CDT
Alnylam Pharmaceuticals (ALNY) announced encouraging results from its phase II study on patisiran.
BIIB: 423.57 (+1.46), ALNY: 118.00 (-2.70), AMGN: 169.10 (+0.64), SNY: 51.59 (+0.03)
Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 22, 12:21PM CDT
Amgen's (AMGN) first quarter 2015 results were impressive and the company raised its earnings outlook for the year.
BIIB: 423.57 (+1.46), ALNY: 118.00 (-2.70), GILD: 104.18 (-1.02), MDCO: 27.84 (+0.25), AMGN: 169.10 (+0.64), AMPE: 2.89 (+0.20), ABBV: 64.52 (+0.91), ATHX: 1.34 (+0.01)
Can the Rally in Alnylam Pharmaceuticals (ALNY) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 6:29AM CDT
Can the Rally in Alnylam Pharmaceuticals (ALNY) Shares Continue?
ALNY: 118.00 (-2.70)
Alnylam Pharmaceuticals
at Investor's Business Daily - Tue Apr 21, 5:48PM CDT
Alnylam Pharmaceuticals (ALNY) disclosed positive midstage testing results for its neurological drug patisiran, used to treat the potentially fatal genetic disorder, transthyretin-mediated amyloidosis. Shares rose rose 1.7% to 120.70.
ALNY: 118.00 (-2.70)
Alnylam Pharmaceuticals Rises 1.70% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Apr 21, 5:16PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $119.01 to a high of $132.99. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $123.72 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 118.00 (-2.70)
Why Alnylam Pharmaceuticals, Inc. Shares Are Soaring Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 21, 12:36PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What's happening: Shares in Alnylam...
ALNY: 118.00 (-2.70), SNY: 51.59 (+0.03)
Alnylam Says Neurological Drug Passes Midstage Study
at Investor's Business Daily - Tue Apr 21, 12:22PM CDT
Alnylam Pharmaceuticals (ALNY) disclosed positive midstage testing results for its neurological drug patisiran, used to treat the potentially fatal disease transthyretin-mediated amyloidosis (TTM), a genetic disorder. The company said patisiran...
ALNY: 118.00 (-2.70)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:22AM CDT
HOG: 56.23 (+0.51), TNXP: 6.73 (+0.21), ALNY: 118.00 (-2.70), LRE: 8.43 (+0.08), LRCX: 78.36 (+0.52), MYL: 72.40 (-1.67), NVGN: 7.40 (-0.30), BIOC: 3.15 (+0.02), NBG: 1.19 (+0.12), VLTC: 15.14 (-1.04), FTNT: 38.07 (-0.01), BCLI: 4.29 (-0.09), SANM: 21.09 (+0.40)
Alnylam's patisiran shows promise of halting neuropathy progression in patients with genetic disorder
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 7:47AM CDT
ALNY: 118.00 (-2.70)
Alnylam Reports 12-Month Clinical Data from Phase 2 Open Label Extension (OLE) Study of Patisiran, an Investigational RNAi Therapeutic for Patients with Familial Amyloidotic Polyneuropathy (FAP)
Business Wire - Tue Apr 21, 5:00AM CDT
--- Based on Promising Results, Company Now Plans to Report 18-Month OLE Clinical Data in Late 2015 -
ALNY: 118.00 (-2.70)
Big Pharmas' Dirty Little Secret About Cholesterol Lowering Drugs
Mark Chapman - at Seeking Alpha - Wed Apr 15, 10:19AM CDT
ESPR: 100.53 (-2.60), ALNY: 118.00 (-2.70), MDCO: 27.84 (+0.25), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41)
Alnylam Reports Publication of New Data on Hemophilia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 3:45PM CDT
Alnylam (ALNY) announced that pre-clinical results on ALN-AT3 were published in Nature Medicine.
BIIB: 423.57 (+1.46), ALNY: 118.00 (-2.70), AMGN: 169.10 (+0.64), AFFX: 12.57 (-0.13)
Alnylam and Collaborators Publish Pre-clinical Study Results in Nature Medicine on ALN-AT3, an Investigational RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)
Business Wire - Mon Apr 13, 10:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication in Nature Medicine of pre-clinical results with ALN-AT3, an investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD). The paper, titled "An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia" (Sehgal et al., Nat Med, doi:10.1038/nm.3847), documents a broad set of pre-clinical data supporting the clinical advancement of ALN-AT3. Among the many findings reported, subcutaneous administration of ALN-AT3 led to potent, dose-dependent, and durable knockdown of AT in wild-type mice, hemophilia A mice, and non-human primates (NHPs). In addition, ALN-AT3 treatment improved hemostasis in hemophilia mice and normalized thrombin generation in a non-human primate "inhibitor" model of hemophilia A (HA). Furthermore, long-term ALN-AT3 administration - even at highly exaggerated doses - was shown to be well tolerated in hemophilia mice, supporting a wide therapeutic index in the disease setting.
ALNY: 118.00 (-2.70)
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 5.96% Rise
Comtex SmarTrend(R) - Fri Apr 10, 4:51PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $108.00 to a high of $114.69. Yesterday, the shares gained 6.0%, which took the trading range above the 3-day high of $109.08 on volume of 726,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 118.00 (-2.70)
Upcoming Events: RNAi And Remyelination At AAN And Pivotal Data From Eleven
EP Vantage - at Seeking Alpha - Thu Apr 09, 4:03PM CDT
Welcome to your weekly digest of approaching regulatory and clinical readouts. Several companies will present data on closely-watched products at the annual meeting of the American Academy of Neurology, taking place in the US capital the week after...
BIIB: 423.57 (+1.46), ALNY: 118.00 (-2.70), GWPH: 113.04 (-0.05)
Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 7:46AM CDT
Alnylam Pharmaceuticals (ALNY) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 49 out of more than 250 industries.
ALNY: 118.00 (-2.70)
Alnylam to Webcast Presentation at 14th Annual Needham Healthcare Conference
Business Wire - Wed Apr 08, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 12:10 p.m. ET at the Westin Grand Central Hotel in New York City.
ALNY: 118.00 (-2.70)
Infinity Pharmaceuticals Exercises Duvelisib Royalty Option - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 01, 2:20PM CDT
Infinity Pharmaceuticals, Inc. announced that it has exercised its option to buy out all future royalty obligations related to the sales of its candidate, duvelisib.
ALNY: 118.00 (-2.70), INFI: 14.71 (-0.28), ABBV: 64.52 (+0.91)
Hospira Presents Data on Retacrit, an Epogen Biosimilar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 9:30AM CDT
Hospira, Inc. presented data from two studies on a proposed biosimilar, Retacrit.
JNJ: 100.43 (+0.13), ALNY: 118.00 (-2.70), PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), HSP: 87.80 (+0.04)
After Yesterday's Decline of 5.13%, Alnylam Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Mon Mar 23, 5:24PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $110.52 to a high of $116.49. Yesterday, the shares fell 5.1%, which took the trading range below the 3-day low of $111.34 on volume of 829,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALNY: 118.00 (-2.70)
